SABE belle BIOMALIFE® BAXTERBIOMA capsules, 60 ST

Abbildung/Farbe ähnlich

SABE belle BIOMALIFE® BAXTERBIOMA capsules are a food supplement based on Limosilactobacillus reuteri Pylopass™.

€31.50*

Content: 60 Stück (€0.53* / 1 Stück)

Prices incl. VAT plus shipping costs (Kann sich je nach Land ändern)

Available, delivery time: 1-3 days ⁴

Product number: RA8078266

Stück: 60

Hersteller:

Product information "SABE belle BIOMALIFE® BAXTERBIOMA capsules"

SABE belle BIOMALIFE® BAXTERBIOMA capsules are a food supplement based on Limosilactobacillus reuteri Pylopass™.

Helicobacter pylori

H. pylori is a bacterium that occurs in the human stomach. It tolerates acidic pH values very well as it produces ammonia. Furthermore, thanks to its spiral structure, it is able to penetrate the mucus layer and anchor itself in the inner stomach wall, where the acidity level is lower. H. pylori infection is the main risk factor for chronic gastritis and a factor favouring peptic ulcer disease, a severe and limited lesion of the mucous membrane of the digestive tract. Some factors favour this type of infection: family predisposition, cigarette smoking, severe stress.

Helicobacter pylori infection is diagnosed by means of

blood test
stool test
Breath test (or breath test)

Typical symptoms of chronic gastritis are Pain in the upper abdomen, a feeling of fullness, nausea, vomiting, belching, loss of appetite, weight loss and indigestion (or poor digestion). Chronic gastritis can also be completely asymptomatic (approx. 20% of cases).

Active ingredients

PYLOPASS™: Several clinical studies have shown that eradication of H. pylori is more successful in patients who take dietary supplements containing specific probiotic strains in addition to pharmacological treatment. One of these is Pylopass™, a tyndalised strain of Limosilactobacillus reuteri. Pylopass™ specifically and selectively binds to H. pylori without affecting other bacterial strains in the intestinal microbiota. Each unit of L. reuteri binds 2-3 H. pylori bacteria. Thanks to this binding, the H. pylori bacterium cannot adhere to the gastric mucosa and is more easily excreted.

In vivo studies show that Pylopass™ reduces the bacterial load of H. pylori, alleviates symptoms and increases the eradication rate of this bacterium in people undergoing pharmacological treatment.

Efficacy study

For Parth's clinical trial (2021), 90 patients were divided into 2 groups. One group received the triple eradication therapy with L. reuteri Pylopass™ for 14 days, the other group only received the triple antibiotic therapy.
The following reduction in the most important side effects of eradication therapy was observed Nausea (60 % vs. 86.67 %, p=0.033), diarrhoea (36.6 % vs. 50 %, p=0.035), constipation (20 % vs. 33.3 %, p=0.026), taste changes (43.3 % vs. 60 %, p=0.047).
Patients treated with Pylopass™ in combination with antibiotic therapy also showed statistically significant improvements in symptoms caused by the infection, such as stomach pain, heartburn, acid reflux, nausea, flatulence and belching.
The eradication rate resulting from the study increased from 66.67% (triple antibiotic therapy group) to 86.67% (triple antibiotic therapy and Pylopass™ group).

Notes

Gluten-free
Naturally lactose-free
Without sweeteners
No added sugar
No preservatives

- C. Holz, "Significant Reduction in Helicobacter pylori load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study," Probiotics & Antimicro. Prot, 2014. - H. Mehling, "Non-Viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a New Approach to Helicobacter pylori Control in Humans", Nutrients, 2013, 5, 3062-3073. - M.H. Emara, "Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: a double-blind placebo-controlled randomised clinical trial", Ther Adv Gastroenterol 2014, Vol 7(1) 4-13. - Lonza, "PylopassTM A new Approach in H. pylori Control - presentazione della materia prima," 2012. - Network Nutrition - IMCD, "Brochure materia prima". - K. Parth et al, "Efficacy of Lactobacillus reuteri Supplementation in Eradication of H. pylori: A Comparison Study with Triple Drug Therapy," JPRI, 33(52B): 151-159, 2021.

Dosage form

Tablets

How to use

Take 2 capsules daily with a large glass of water. Preferably take one capsule after breakfast and one capsule after dinner.
Advice: Suitable for children. During pregnancy and breastfeeding.

Ingredients

Ingredients: FILLERS: CELLULOSE, DICALCIUM PHOSPHATE; LIMOSILACTOBACILLUS REUTERI DSM 17648 (NON-LIVING CELLS, MALTODEXTRIN); COATING AGENT (CAPSULE): HYDROXYPROPYL METHYLCELLULOSE; SEPARATING AGENT: MAGNESIUM SALTS OF FATTY ACIDS, SILICON DIOXIDE; COLOUR: CALCIUM CARBONATE.
Composition per daily dose (2 capsules): L. reuteri Pylopass™* 200 mg (equal to ^2x1010inactivated cells). *Pylopass™ is a trademark from Novozymes A/S, Denmark.

Glutenfrei:	Ja
Laktosefrei:	Ja
Vegetarier:	Ja
Stück:	60

0 of 0 reviews

Leave a review!

Share your experiences with other customers.

Your rating*

Excellent

Displayed Name*

Your E-mail address*

Title*

Your review*

Fields marked with asterisks (*) are required.

Cancel

To continue, enter the characters shown above*

Display reviews in current language only.

No reviews found. Share your insights with others.

Warnhinweise - SABE belle BIOMALIFE® BAXTERBIOMA capsules

Anwendungshinweise

Produktempfehlungen für Sie

Our recommendation

15.03 %

SABE belle REFLUXcontrol sticks

SABE belle REFLUXcontrol Sticks are a medical device for oral use for the treatment of gastro-oesophageal reflux, heartburn, oesophagitis, irritable cough and belching due to gastric reflux.

Content: 20 Stück

€14.36* €16.90*

15 %

SABE belle REFLUXcontrol chewable tablets

SABE belle REFLUXcontrol chewable tablets are a medical product that reduces gastro-oesophageal reflux, relieves gastric acidity and protects the gastric mucosa.

Content: 24 Stück

€7.99* €9.40*

Cutsomers also bought

SABE belle BIOMALIFE® BUTIRBIOMA enteric coated tablets

The SABE belle BIOMALIFE® BUTIRBIOMA tablets are a dietary supplement based on sodium butyrate. Each tablet contains 625 mg of modified-release sodium butyrate.

Content: 30 Stück

€24.70*

SABE belle BIOMALIFE® BAXTERBIOMA capsules, 60 ST

Dosage form

How to use

Ingredients

Anwendungshinweise

Wir bleiben in Kontakt!